Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Siddharth SinghMathurin FumeryAbha G SinghNamrata SinghLarry J ProkopParambir S DulaiWilliam J SandbornJeffrey R CurtisPublished in: Arthritis care & research (2020)
Based on meta-analysis, as compared to TNFi, tocilizumab may be associated with a reduced risk of MACE, whereas csDMARDs may be associated with an increased risk of MACE and stroke.
Keyphrases
- cardiovascular events
- rheumatoid arthritis
- systematic review
- coronary artery disease
- rheumatoid arthritis patients
- cardiovascular disease
- disease activity
- atrial fibrillation
- meta analyses
- juvenile idiopathic arthritis
- case control
- randomized controlled trial
- type diabetes
- systemic lupus erythematosus
- drug induced